Diabest Botanical Drugs

Company Overview

Snapshot

Founded in August 2011 by Yitshak Francis and Tovit Rosenzweig, Diabest Botanical Drugs operates with 1–10 employees. In August 2011, the company developed a Sarcopoterium Spinosum extract for the treatment of type II diabetes.

Business overview

Diabest Botanical Drugs is a Health Tech & Life Sciences company focused on developing botanical dietary supplements to support blood glucose levels. The company's core technology involves a proprietary botanical extract method and optimized growing protocol for Sarcopoterium spinosum, aiming to maintain healthy blood sugar levels and prevent diabetic complications. While primarily focused on type-2 diabetes, its technology has potential applications across a wider range of metabolic disorders, serving global markets within the pharmaceuticals and biotechnology sectors.

Company Intelligence Q&A

What is Diabest Botanical Drugs' primary focus?

Diabest Botanical Drugs focuses on developing a botanical dietary supplement to support blood glucose levels, primarily targeting type-2 diabetes and other metabolic diseases.

What is the key ingredient in Diabest Botanical Drugs' supplement?

The key ingredient in Diabest Botanical Drugs' supplement is an extract based on Sarcopoterium spinosum, which is utilized for its anti-diabetic effects.

When was Diabest Botanical Drugs founded?

Diabest Botanical Drugs was founded in August 2011.

Who are the founders of Diabest Botanical Drugs?

Diabest Botanical Drugs was co-founded by Yitshak Francis and Tovit Rosenzweig.

What is the current status of Diabest Botanical Drugs?

Diabest Botanical Drugs is currently non-active, having ceased operations in September 2023.